Celularity (CELU) Stock Price, News & Analysis

Company Overview

Celularity, Inc. is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.

Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs. The company has also developed placental-derived biomaterial products intended to support wound care and tissue repair.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. The company was founded by Robert J. Hariri, M.D., Ph.D., who has served in senior leadership roles, including chief executive officer and chairman. Its products and clinical programs are intended for use in the United States and other markets where regulatory authorization or clinical development is available.

Key Stats

• Today's Range: $1.28 to $1.37
• 50-Day Range: $0.64 to $2.10
• 52-Week Range: $0.56 to $2.55
• Volume: 54,521 shs
• Average Volume: 202,372 shs
• Market Capitalization: $39.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Celularity Stock Analysis - MarketRank™

Celularity scored higher than 14% of companies evaluated by MarketBeat, and ranked 842nd out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Celularity has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Celularity has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Celularity is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celularity is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.43% of the float of Celularity has been sold short.

Short Interest Ratio / Days to Cover

Celularity has a short interest ratio ("days to cover") of 2.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Celularity has recently decreased by 56.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celularity does not currently pay a dividend.

Dividend Growth

Celularity does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.50

News Sentiment

Celularity has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Celularity this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for CELU on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Celularity to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celularity insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.30% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.02% of the stock of Celularity is held by institutions.

Company Calendar

• Last Earnings: 9/29/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CELU
• CIK: 1752828
• Web: www.celularity.com
• Phone: 908-768-2170
• Fax: N/A
• Employees: 115
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($3.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$91.72 million
• Net Margins: -345.45%
• Pretax Margin: -345.43%
• Return on Equity: N/A
• Return on Assets: -77.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.15
• Quick Ratio: 0.15

Sales & Book Value

• Annual Sales: $26.55 million
• Price / Sales: 1.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.32) per share
• Price / Book: -1.02

Miscellaneous

• Outstanding Shares: 28,950,000
• Free Float: 23,938,000
• Market Cap: $39.08 million
• Optionable: Optionable
• Beta: 0.79